journal article·2026-01Open access

Arid1a Deficiency Drives Aristolochic Acid‐Induced Liver Tumorigenesis through Ctnnb1 Mutation and Defective Nucleotide Excision Repair

Lan Wang, Shi‐Hao Bai, Shu‐Jin Song, Xiao‐Li Zhang, Xue‐Ying Shang, Zhao‐Ning Lu, Xiao‐Fang Cui, Xin‐Le Zhu, Ze‐Guang Han

Advanced Science· Volume 13· Issue 3

Abstract

Abstract ARID1A , which encodes an important subunit of SWI/SNF complex, is frequently mutated in non‐malignant tissues and tumors. However, how ARID1A loss enables environmental carcinogens to initiate tumorigenesis remains unknown. Here, liver‐specific Arid1a ‐deficient ( Arid1a LKO ) mice are exposed to aristolochic acid I (AAI), a potent herbal carcinogen. Notably, AAI dramatically accelerated hepatocarcinogenesis in Arid1a ‐deficient livers, accompanied by a specific 3′ splice‐site mutation in Ctnnb1 in most tumors and adjacent non‐tumorous tissues. This mutation results in exon 3 skipping and subsequent β‐catenin activation. Single‐nucleus RNA‐seq coupled with phylogenetic analyses reveals AAI‐induced tumor microenvironment alteration and clonal expansion of β‐catenin‐activated cells. Conversely, inhibition of β‐catenin signaling significantly suppresses AAI‐induced tumors in the context of Arid1a loss. Mechanistically, Arid1a deficiency transcriptionally represses the expression of critical genes related to nucleotide excision repair, which removes AAI‐derived DNA adducts, due to SWI/SNF complex dysfunction. Simultaneously, it upregulates Nqo1, a key enzyme enhancing AAI bioactivation and AAI‐DNA adduct formation. This dual‐hit mechanism, characterized by impaired DNA repair and heightened genotoxicity, explains synergistic carcinogenesis. The study unveils ARID1A as a guardian against environmental carcinogens and proposes β‐catenin blockade for precision prevention in high‐risk patients with ARID1A ‐mutant benign liver diseases.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Chromatin Remodeling and Cancer · Cancer Genomics and Diagnostics · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Systems Biomedicine (Ministry of Education) and State Key Laboratory of Medical Genomics Shanghai Center for Systems Biomedicine Shanghai Jiao Tong University Shanghai 200240 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Natural Science Foundation of Shanghai Municipality · Higher Education Discipline Innovation Project · Fundamental Research Funds for the Central Universities

References (63)

Show source-provided references
1. 10.1038/ng.262810.1038/ng.2628 ↗
2. 10.1038/s41571‐020‐0357‐310.1038/s41571‐020‐0357‐3 ↗
3. 10.1016/j.ccell.2020.11.00210.1016/j.ccell.2020.11.002 ↗
4. 10.1038/s41568‐021‐00335‐310.1038/s41568‐021‐00335‐3 ↗
5. 10.1158/2159‐8290.CD‐22‐014510.1158/2159‐8290.CD‐22‐0145 ↗
6. 10.1038/s41568‐022‐00529‐310.1038/s41568‐022‐00529‐3 ↗
7. 10.1038/s41586‐021‐03836‐110.1038/s41586‐021‐03836‐1 ↗
8. 10.1016/j.cell.2019.03.02610.1016/j.cell.2019.03.026 ↗
9. 10.1146/annurev‐physiol‐061121‐04004810.1146/annurev‐physiol‐061121‐040048 ↗
10. 10.1002/hep.3048710.1002/hep.30487 ↗
11. 10.1016/j.ebiom.2019.03.02110.1016/j.ebiom.2019.03.021 ↗
12. 10.1371/journal.pone.014304210.1371/journal.pone.0143042 ↗
13. 10.1126/sciadv.adh443510.1126/sciadv.adh4435 ↗
14. 10.1016/j.stem.2016.03.00110.1016/j.stem.2016.03.001 ↗
15. 10.1016/j.ccell.2017.10.00710.1016/j.ccell.2017.10.007 ↗
16. 10.1146/annurev‐cancerbio‐062822‐12355810.1146/annurev‐cancerbio‐062822‐123558 ↗
17. 10.1038/s41591‐018‐0012‐z10.1038/s41591‐018‐0012‐z ↗
18. 10.1158/2159‐8290.CD‐14‐084910.1158/2159‐8290.CD‐14‐0849 ↗
19. 10.1158/1078‐0432.CCR‐18‐422210.1158/1078‐0432.CCR‐18‐4222 ↗
20. 10.1038/s41568‐022‐00494‐x10.1038/s41568‐022‐00494‐x ↗
21. 10.1002/ijc.2868110.1002/ijc.28681 ↗
22. 10.1126/scitranslmed.aan644610.1126/scitranslmed.aan6446 ↗
23. 10.1002/hep.3086310.1002/hep.30863 ↗
24. 10.1016/j.jhep.2018.06.00910.1016/j.jhep.2018.06.009 ↗
25. 10.1016/j.jhep.2019.12.01410.1016/j.jhep.2019.12.014 ↗
26. 10.1016/j.cell.2019.08.05210.1016/j.cell.2019.08.052 ↗
27. 10.1038/ng.229110.1038/ng.2291 ↗
28. 10.1002/hep.2719810.1002/hep.27198 ↗
29. 10.1016/j.ccell.2019.04.00710.1016/j.ccell.2019.04.007 ↗
30. 10.1158/1078‐0432.CCR‐18‐229310.1158/1078‐0432.CCR‐18‐2293 ↗
31. 10.1371/journal.pone.020077610.1371/journal.pone.0200776 ↗
32. 10.1038/ng.325210.1038/ng.3252 ↗
33. 10.1038/s41467‐022‐29960‐810.1038/s41467‐022‐29960‐8 ↗
34. 10.1038/s41586‐024‐07054‐310.1038/s41586‐024‐07054‐3 ↗
35. 10.1146/annurev‐cancerbio‐050216‐12200210.1146/annurev‐cancerbio‐050216‐122002 ↗
36. 10.1371/journal.pcbi.100366510.1371/journal.pcbi.1003665 ↗
37. 10.1038/s41586‐019‐1631‐310.1038/s41586‐019‐1631‐3 ↗
38. 10.1016/j.jcmgh.2020.07.01210.1016/j.jcmgh.2020.07.012 ↗
39. 10.1038/nbt.423110.1038/nbt.4231 ↗
40. 10.1038/nature2106510.1038/nature21065 ↗
41. 10.1016/j.molcel.2019.07.02810.1016/j.molcel.2019.07.028 ↗
42. 10.1038/s41596‐020‐0292‐x10.1038/s41596‐020‐0292‐x ↗
43. 10.1038/s41467‐021‐21246‐910.1038/s41467‐021‐21246‐9 ↗
44. 10.1038/nrm382210.1038/nrm3822 ↗
45. 10.1093/carcin/bgg11910.1093/carcin/bgg119 ↗
46. 10.1002/em.2064210.1002/em.20642 ↗
47. 10.1016/j.redox.2021.10195010.1016/j.redox.2021.101950 ↗
48. 10.1038/s41588‐019‐0541‐510.1038/s41588‐019‐0541‐5 ↗
49. 10.1016/j.celrep.2016.09.00310.1016/j.celrep.2016.09.003 ↗
50. 10.1158/0008‐5472.CAN‐21‐076310.1158/0008‐5472.CAN‐21‐0763 ↗
51. 10.1016/j.stem.2019.06.00810.1016/j.stem.2019.06.008 ↗
52. 10.1172/JCI15451510.1172/JCI154515 ↗
53. 10.1073/pnas.040487510110.1073/pnas.0404875101 ↗
54. Abe H. · Int. J. Clin. Exp. Pathol. · 2015 · 8 · 2763
55. 10.1186/s13046‐015‐0164‐310.1186/s13046‐015‐0164‐3 ↗
56. 10.1158/2159‐8290.CD‐24‐012810.1158/2159‐8290.CD‐24‐0128 ↗
57. 10.1073/pnas.080180210510.1073/pnas.0801802105 ↗
58. 10.1016/j.canlet.2022.21586910.1016/j.canlet.2022.215869 ↗
59. 10.1002/biot.20140082110.1002/biot.201400821 ↗
60. 10.1038/emboj.2013.9510.1038/emboj.2013.95 ↗
61. 10.1093/toxres/tfac00210.1093/toxres/tfac002 ↗
62. 10.1021/tx300088910.1021/tx3000889 ↗
63. 10.1093/carcin/18.5.105510.1093/carcin/18.5.1055 ↗